Physician profile
David M Whitney
NPI 1699113175
$12,380.72
in general payments reported to CMS, 2019-2025
47 companies · $2,315 in 2025
The $2,315 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,298 · 2020: $1,460 · 2021: $1,064 · 2022: $1,999 · 2023: $1,909 · 2024: $2,336 · 2025: $2,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,546 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,545.95 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,727.81 | 2019-2025 | Infinity |
| Abbvie INC. | $1,702.23 | 2021-2025 | Botox, Duopa, Ubrelvy |
| Boston Scientific Corporation | $1,448.20 | 2020-2025 | Vercise, General - Dbs |
| Mdd US Operations, LLC | $923.91 | 2022-2025 | Gocovri, Gocovri |
| Neurocrine Biosciences, INC. | $505.22 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $481.21 | 2022-2025 | Qelbree |
| Merz Pharmaceuticals, LLC | $474.12 | 2022-2024 | Xeomin, Inbrija |
| Ucb, INC. | $431.04 | 2019-2024 | Rystiggo, Briviact |
| Kyowa Kirin, INC. | $365.39 | 2020-2024 | Nourianz |
| Ge Healthcare | $355.12 | 2021-2025 | |
| Lilly USA, LLC | $313.86 | 2019-2025 | Kisunla, Amyvid |
| Eisai INC. | $307.45 | 2022-2025 | |
| Insightec,INC | $303.09 | 2023-2025 | Exablate |
| Lundbeck LLC | $277.72 | 2021-2025 | Vyepti |
| Allergan, INC. | $264.53 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Whitney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.